Healthcare -
Medical - Diagnostics & Research - NYSE - NL
$ 40.31
5.36 %
$ 8.71 B
Market Cap
106.08
P/E
1. INTRINSIC VALUE
Balance Sheet
Qiagen N.V.
| Current Assets | 1.96 B |
| Cash & Short-Term Investments | 1.15 B |
| Receivables | 349 M |
| Other Current Assets | 458 M |
| Non-Current Assets | 3.73 B |
| Long-Term Investments | 0 |
| PP&E | 754 M |
| Other Non-Current Assets | 2.98 B |
| Current Liabilities | 544 M |
| Accounts Payable | 83.3 M |
| Short-Term Debt | 53.5 M |
| Other Current Liabilities | 407 M |
| Non-Current Liabilities | 1.58 B |
| Long-Term Debt | 1.34 B |
| Other Non-Current Liabilities | 241 M |
EFFICIENCY
Earnings Waterfall
Qiagen N.V.
| Revenue | 1.98 B |
| Cost Of Revenue | 653 M |
| Gross Profit | 1.32 B |
| Operating Expenses | 1.23 B |
| Operating Income | 97.7 M |
| Other Expenses | 14.1 M |
| Net Income | 83.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Qiagen N.V.
| Net Income | 83.6 M |
| Depreciation & Amortization | 222 M |
| Capital Expenditures | -167 M |
| Stock-Based Compensation | 43.6 M |
| Change in Working Capital | 135 M |
| Others | 325 M |
| Free Cash Flow | 506 M |
Wall Street Analysts Price Targets
Qiagen N.V.
Wall Street analysts predict an average 1-year price target for QGEN of $48.3 , with forecasts ranging from
a
low of
$46 to a high of $50 .
QGEN Lowest Price Target
Wall Street Target
46 USD
14.12%
QGEN Average Price Target
Wall Street Target
48.3 USD
19.90%
QGEN Highest Price Target
Wall Street Target
50 USD
24.04%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
1.32 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Qiagen N.V.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting strong performances across many growth drivers. Net sales grew approximately 5% (+7% at constant exchange rates, CER) to about $483 million in Q1 2025, surpassing the previously communicated outlook for about 3% CER growth (4% CER core business excluding discontinued.
businesswire.com
- 2 weeks ago
QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAprep& Plasmodium Kit and two companion assays to support malaria research and surveillance efforts. This new solution combines sample preparation and quantitative PCR (qPCR) into a single workflow, providing a rapid and accessible tool for detecting malaria-causing parasites from blood samples. Malaria remains one of the world's most pressing public health cha.
businesswire.com
- 2 weeks ago
QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN's website here. QIAGEN will provide printed copies of the 2024 Annual Report to shareholders free of charge upon request. To obtain a printed copy of the 20.
businesswire.com
- 2 weeks ago
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.
zacks.com
- 1 month ago
QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel
QIAGEN wins the FDA's clearance for the second QIAstat-Dx mini gastrointestinal panel.
zacks.com
- 1 month ago
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further strengthening its syndromic testing portfolio in the United States. This marks QIAGEN's second FDA clearance of a QIAstat-Dx panel in 2025, and builds on the authorization of five panels for use on the QIAstat-Dx system within the last 10 mont.
businesswire.com
- 1 month ago
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringement, reinforcing its commitment to protecting the scientific advancements behind its proprietary QuantiFERON technology. The complaint, filed in the Local Division of the Court of First Instance of the Unified Patent Court (UPC) in Duesseldorf, Germany, concerns European Patent EP 2 276 883 B2. This.
businesswire.com
- 1 month ago
Qiagen N.V.: Some Clarity Needed Before Buying The Dip
Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below.
seekingalpha.com
- 1 month ago
2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62%
Stock splits can be undertaken for several reasons. They can bring a stock's price down to make it more affordable for a wider range of investors.
fool.com
- 1 month ago
FFPE Tissue Samples for Genomics Study & Analysis Market to Cross US$ 1.5 Bn by 2034 with a Robust CAGR of 5.1%, Led by Key Players BioChain Institute, Amsbio, Cureline, Discovery Life Sciences, and QIAGEN - TMR
The FFPE tissue samples for genomics study & analysis market is poised for significant growth, driven by rising cancer incidence, advancements in genomic technologies, and an increasing focus on personalized medicine. These samples play a crucial role in cancer research, enabling detailed genetic profiling and better therapeutic strategies. Despite challenges like regulatory constraints and high costs, emerging markets and innovations in sample preservation present promising growth opportunities for industry players. The FFPE tissue samples for genomics study & analysis market is poised for significant growth, driven by rising cancer incidence, advancements in genomic technologies, and an increasing focus on personalized medicine. These samples play a crucial role in cancer research, enabling detailed genetic profiling and better therapeutic strategies. Despite challenges like regulatory constraints and high costs, emerging markets and innovations in sample preservation present promising growth opportunities for industry players.
globenewswire.com
- 2 months ago
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=40667482 Browse in-depth TOC on "Molecular Infectious Disease Testing Market" 539 - Tables61 - Figures448 - Pages An advancement in multiplex testing which could transform the molecular infectious disease testing market, is the integrated, fully automated multiplex diagnostic platforms. It will combine testing for multiple pathogens in a single reaction with the advantage of full automation, right from sample preparation to result interpretation. The automation of multiplex testing minimizes the chance of human error, enhances throughput, and accelerates the diagnostic process. These are the factors why this technology will thrive in environments of high demand such as hospitals, urgent care centers, and public health labs. The more these systems become user-friendly and affordable, the greater their potential will be to enhance access to multiplex tests in more rapid and comprehensive infectious disease surveillance and management across a range of healthcare settings. Based on product & service, the global molecular infectious disease testing market has been segmented into reagents & kits, instruments, and services & software. The fastest-growing segment within the molecular infectious disease testing market is the reagents and kits, mainly due to their critical role in making it possible for an accurate and efficient diagnosis. The growing use of molecular testing in clinical practices has caused the demand for good quality reagents and kits since they are indispensable in PCR, next-generation sequencing, and other molecular assays. The expansion of testing volumes within diagnostic laboratories and hospitals further propels the growth. Moreover, increased accessibility to ready-to-use, standardized kits and reagents that enhance sensitivity and reduce the turnaround time accelerate their demand in the molecular infectious disease testing market. Categorized by type, the molecular infectious disease testing market is segmented into single plex testing and multiplex testing. The multiplex testing segment is expected to witness the highest growth rate in the molecular infectious disease testing market because of its ability to test for more than one pathogen in a single test. Such capability can considerably reduce the testing time and cost while improving efficiency and accuracy of diagnostics. This is very helpful in complex infections, which could be due to multiple pathogens. The increasing demand for this type of testing in healthcare settings having high patient numbers is further due to the need for comprehensive, timely diagnostic solutions. Technological advancements in multiplex assay platforms have made this testing become indispensable in improving the clinical outcome, enhancing infection control measures. Key players in the molecular infectious disease testing market include Danaher (US), F. Hoffmann- La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). These companies have a diversified product portfolio and a good geographic presence also. With growing global burden of infectious diseases and increasing need for accurate diagnostics, such players are well-positioned to develop novel diagnostic technologies and further expand their offerings. They expand their market share through subsidiaries across the world based on the strength of their R&D capabilities and diversified product and services portfolios. Their product launches, agreements, acquisitions, and partnerships further enhance their portfolio while expanding the reach of their global business. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=40667482 The key players operating in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherlands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), DiaSorin S.p.A. (Italy), and Seegene Inc. (South Korea). The market players have adopted several strategies such as advanced product development, partnerships, expansions, and acquisitions to strengthen their market position. The organic and inorganic strategies have allowed the market players to expand across geographies through the provision of advanced molecular infectious disease tests. Danaher emerged as the leader in the molecular infectious disease testing market in 2023. Its position as the leader in the market across the US serves as a platform from where it can penetrate more into the developing economies and build its global presence across more geographies. The company is also responsible for innovation in its products to cater to the varied needs of customers worldwide. This has assisted the company in building on its leadership position in the market. Additionally, the company also adopts certain organic growth strategies by launching new products and seeking relevant regulatory clearances. For example, in March 2024, the US FDA cleared the Xpert Xpress GBS test. In November 2022, it launched the Xpert Xpress MVP, a multiplexed PCR test. Such strategic steps have helped the company stay continuously in the lead in the molecular infectious disease testing market. F. Hoffmann-La Roche Ltd is a significant global player in the molecular infectious disease testing market. Its broad portfolio and presence in all parts of the world have helped it sustain its competitive advantage. Roche has a very good direct and indirect distribution network around the world, which enables it to balance out demand fluctuations in the different markets. Its strategic emphasis on organic as well as inorganic growth strategies makes the company stronger in the marketplace. For example, in September 2024, Roche launched the cobas Respiratory flex test. This is the first test by Roche using Roche's innovative and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology identifies as many as 15 pathogens in a single PCR test by using multiplex polymerase chain reaction testing combined with color, temperature, and data processing. All these strategies, coupled with its strong presence in the market, have given Roche further opportunities to enhance its position within the molecular infectious disease testing market. bioMérieux is a prominent player in the molecular infectious disease testing market. Its robust position in the market is due to extensive distribution networks in America, Europe, the Middle East & Africa, and Asia Pacific. High investment in research & development, coupled with organic growth strategies, also helps bioMérieux strengthen its position in the market. Such initiatives include the launching of products and gaining appropriate regulatory approvals in order to extend its market shares. In December 2024, bioMérieux announced that the company's BIOFIRE FILMARRAY Tropical Fever (TF) Panel has achieved USD FDA Special 510(k) clearance. This new, innovative PCR-based testing solution brings fast and accurate pathogen identification in patients suffering from unexplained fever to clinicians, optimizing the treatment overall. For more information, Inquire Now! Related Reports: Molecular Diagnostics Market Veterinary Diagnostics Market Molecular Quality Controls Market IVD Contract Manufacturing Market Genetic Testing Market Get access to the latest updates on Molecular Infectious Disease Testing Companies and Molecular Infectious Disease Testing Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
https://www.prnewswire.com
- 2 months ago
QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand
QGEN's performance benefits from a resilient portfolio in the fourth quarter of 2024.
zacks.com
- 2 months ago
8. Profile
Summary
Qiagen N.V. QGEN
COUNTRY
NL
INDUSTRY
Medical - Diagnostics & Research
MARKET CAP
$ 8.71 B
Dividend Yield
0.00%
Description
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Contact
Hulsterweg 82, Venlo, 5912 PL
https://www.qiagen.com
IPO
Date
June 28, 1996
Employees
5067
Officers
Mr. Jean-Pascal Viola
Senior Vice President & Head of Corporate Strategy and Business Development
Mr. John Gilardi
Vice President of Corporate Communications & Investor Relations
Dr. Thomas Schweins
Senior Vice President of Life Science Business Area
Dr. Thomas Theuringer
Senior Director & Head of External Communications
Dr. Dominic John
Vice President of Marketing & Product Management
Dr. Roland Sackers
Chief Financial Officer, MD & Member of Management Board
Mr. Thierry Bernard
Chief Executive Officer, MD & Member of Management Board
Ms. Stephany Foster
Senior Vice President & Head of Human Resources
Dr. Jonathan G. Sheldon Ph.D.
Senior Vice President & Head of the QIAGEN Digital Insights Business Area
Mr. Antonio Santos
Senior Vice President & Head of Global Operations